Does CDKN2A Loss Predict Palbociclib Benefit?
نویسندگان
چکیده
منابع مشابه
Does CDKN2A loss predict palbociclib benefit?
Palbociclib, an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6, was recently approved by the U.S. Food and Drug Administration in combination with letrozole for postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer. Patients with loss of CDKN2A (p16), an inherent negative regulator of cyclin-dependent kinases 4 and 6, were not separately st...
متن کاملDoes loss of consciousness predict neuropsychological decrements after concussion?
OBJECTIVE To investigate the importance of loss of consciousness (LOC) in predicting neuropsychological test performance in a large sample of patients with head injury. DESIGN Retrospective comparison of neuropsychological test results for patients who suffered traumatic LOC, no LOC, or uncertain LOC. SETTING Allegheny General Hospital, Pittsburgh, Pennsylvania. PATIENTS The total number ...
متن کاملDoes organic farming benefit biodiversity?
The intensification and expansion of modern agriculture is amongst the greatest current threats to worldwide biodiversity. Over the last quarter of the 20th century, dramatic declines in both range and abundance of many species associated with farmland have been reported in Europe, leading to growing concern over the sustainability of current intensive farming practices. Purportedly sustainable...
متن کاملDoes Airport Regulation Benefit Consumers?
Airport regulation is aimed to impose price caps or other schemes on services supplied by airports to airlines that use them. However, it is not clear that regulation benefits the final consumers, the passengers. In the context of a very simple model, this paper finds out that this doesn’t always happen, and that passengers may be worse off with price capping than in an unregulated equilibrium....
متن کاملCDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Cyclin D-CDK4/6 are the first CDK complexes to be activated in the G1 phase in response to oncogenic pathways. The specific CDK4/6 inhibitor PD0332991 (palbociclib) was recently approved by the FDA and EMA for treatment of advanced ER-positive breast tumors. Unfortunately, no reliable predictive tools are available for identifying potentially responsive or insensitive tumors. We had shown that ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Oncology
سال: 2015
ISSN: 1718-7729
DOI: 10.3747/co.22.2700